Left Atrial Appendage Occluder

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ADEL
ADELKorea - Seoul
1 program
Removal or leaving of LAA occludersN/A1 trial
Active Trials
NCT05014477UnknownEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ADELRemoval or leaving of LAA occluders

Clinical Trials (1)

NCT05014477ADELRemoval or leaving of LAA occluders

Therapy Strategies After LAA Occluder Device Embolization

Start: Sep 2020Est. completion: Dec 2023
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space